Notwithstanding encouraging clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial opposition from pharmacy benefit managers. Such organizations are often creating obstacles to coverage, like steep expense restrictions and prior authorization that restrict patient … Read More